A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2

S. A. Rosenberg, M. T. Lotze, L. M. Muul, S. Leitman, A. E. Chang, John Vetto, C. A. Seipp, C. Simpson

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

A new approach to cancer therapy has been developed based on the adoptive transfer of autologous lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (IL-2). Forty-one patients with advanced cancer who have failed all standard treatments were treated in this experimental protocol. Fourteen patients experienced an objective regression of cancer, including one patients with metastatic melanoma who underwent a complete regression. Objective responses were seen in patients with colorectal cancer, renal cell cancer, melanoma, and lung adenocarcinoma. The sites of tumor regression included subcutaneous tissue, lung, and liver. The major side effect of therapy resulted from the administration of high-dose IL-2 and was manifested primarily as fluid retention, resulting in a generalized capillary permeability leak syndrome. This approach to adoptive immunotherapy represents a promising approach to the therapy of patients with metastatic cancer. Attempts to increase the potency and decrease the toxicity of therapy and extend this treatment to patients with smaller tumor burdens are in progress.

Original languageEnglish (US)
Pages (from-to)262-272
Number of pages11
JournalSurgery
Volume100
Issue number2
StatePublished - 1986
Externally publishedYes

Fingerprint

Lymphokine-Activated Killer Cells
Interleukin-2
Neoplasms
Melanoma
Capillary Leak Syndrome
Therapeutics
Adoptive Immunotherapy
Adoptive Transfer
Subcutaneous Tissue
Capillary Permeability
Tumor Burden
Renal Cell Carcinoma
Colorectal Neoplasms
Lung Neoplasms
Lung
Liver

ASJC Scopus subject areas

  • Surgery

Cite this

Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Vetto, J., ... Simpson, C. (1986). A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2. Surgery, 100(2), 262-272.

A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2. / Rosenberg, S. A.; Lotze, M. T.; Muul, L. M.; Leitman, S.; Chang, A. E.; Vetto, John; Seipp, C. A.; Simpson, C.

In: Surgery, Vol. 100, No. 2, 1986, p. 262-272.

Research output: Contribution to journalArticle

Rosenberg, SA, Lotze, MT, Muul, LM, Leitman, S, Chang, AE, Vetto, J, Seipp, CA & Simpson, C 1986, 'A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2', Surgery, vol. 100, no. 2, pp. 262-272.
Rosenberg, S. A. ; Lotze, M. T. ; Muul, L. M. ; Leitman, S. ; Chang, A. E. ; Vetto, John ; Seipp, C. A. ; Simpson, C. / A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2. In: Surgery. 1986 ; Vol. 100, No. 2. pp. 262-272.
@article{52fe50957112439482fa4504014dc9b5,
title = "A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2",
abstract = "A new approach to cancer therapy has been developed based on the adoptive transfer of autologous lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (IL-2). Forty-one patients with advanced cancer who have failed all standard treatments were treated in this experimental protocol. Fourteen patients experienced an objective regression of cancer, including one patients with metastatic melanoma who underwent a complete regression. Objective responses were seen in patients with colorectal cancer, renal cell cancer, melanoma, and lung adenocarcinoma. The sites of tumor regression included subcutaneous tissue, lung, and liver. The major side effect of therapy resulted from the administration of high-dose IL-2 and was manifested primarily as fluid retention, resulting in a generalized capillary permeability leak syndrome. This approach to adoptive immunotherapy represents a promising approach to the therapy of patients with metastatic cancer. Attempts to increase the potency and decrease the toxicity of therapy and extend this treatment to patients with smaller tumor burdens are in progress.",
author = "Rosenberg, {S. A.} and Lotze, {M. T.} and Muul, {L. M.} and S. Leitman and Chang, {A. E.} and John Vetto and Seipp, {C. A.} and C. Simpson",
year = "1986",
language = "English (US)",
volume = "100",
pages = "262--272",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2

AU - Rosenberg, S. A.

AU - Lotze, M. T.

AU - Muul, L. M.

AU - Leitman, S.

AU - Chang, A. E.

AU - Vetto, John

AU - Seipp, C. A.

AU - Simpson, C.

PY - 1986

Y1 - 1986

N2 - A new approach to cancer therapy has been developed based on the adoptive transfer of autologous lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (IL-2). Forty-one patients with advanced cancer who have failed all standard treatments were treated in this experimental protocol. Fourteen patients experienced an objective regression of cancer, including one patients with metastatic melanoma who underwent a complete regression. Objective responses were seen in patients with colorectal cancer, renal cell cancer, melanoma, and lung adenocarcinoma. The sites of tumor regression included subcutaneous tissue, lung, and liver. The major side effect of therapy resulted from the administration of high-dose IL-2 and was manifested primarily as fluid retention, resulting in a generalized capillary permeability leak syndrome. This approach to adoptive immunotherapy represents a promising approach to the therapy of patients with metastatic cancer. Attempts to increase the potency and decrease the toxicity of therapy and extend this treatment to patients with smaller tumor burdens are in progress.

AB - A new approach to cancer therapy has been developed based on the adoptive transfer of autologous lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (IL-2). Forty-one patients with advanced cancer who have failed all standard treatments were treated in this experimental protocol. Fourteen patients experienced an objective regression of cancer, including one patients with metastatic melanoma who underwent a complete regression. Objective responses were seen in patients with colorectal cancer, renal cell cancer, melanoma, and lung adenocarcinoma. The sites of tumor regression included subcutaneous tissue, lung, and liver. The major side effect of therapy resulted from the administration of high-dose IL-2 and was manifested primarily as fluid retention, resulting in a generalized capillary permeability leak syndrome. This approach to adoptive immunotherapy represents a promising approach to the therapy of patients with metastatic cancer. Attempts to increase the potency and decrease the toxicity of therapy and extend this treatment to patients with smaller tumor burdens are in progress.

UR - http://www.scopus.com/inward/record.url?scp=0022536155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022536155&partnerID=8YFLogxK

M3 - Article

C2 - 3526604

AN - SCOPUS:0022536155

VL - 100

SP - 262

EP - 272

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

IS - 2

ER -